Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Newly published study shows that re-treatment with Pegasys® (peginterferon alfa-2a) provides hepatitis C patients with a second chance for a cure
May 5th, 2009
New data published in Annals of Internal Medicine show that re-treatment with Pegasys® (peginterferon alfa-2a) plus Copegus® (ribavirin) provides previously-treated hepatitis C patients a second chance for a cure. The study results demonstrated that patients most likely to respond to re-treatment could be identified after only 12 weeks, allowing patients and their doctors to be confident early on about the likelihood of success. [i] "While tremendous advances in hepatitis C treatment have cured many hepatitis C patients, a significant proportion of patients do not achieve success with their first treatment course. This is leading to a large and...
Source: Cancer Weekly (2009-05-05)
|
